STOCK TITAN

Core Scientific (CORZ) director awarded 18,575 restricted stock units

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Core Scientific, Inc. director Rozov Yadin reported an award of 18,575 shares of common stock on February 4, 2026, coded as an acquisition at a price of $0 per share. This reflects a grant rather than an open-market purchase.

The award represents a restricted stock unit grant that will vest in full on February 3, 2027, if Yadin continues to serve as a non-employee director through that date. After this grant, Yadin beneficially owns 454,162 shares of Core Scientific common stock in direct ownership.

Positive

  • None.

Negative

  • None.
Insider Rozov Yadin
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 18,575 $0.00 --
Holdings After Transaction: Common Stock — 454,162 shares (Direct)
Footnotes (1)
  1. [object Object]
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rozov Yadin

(Last) (First) (Middle)
C/O CORE SCIENTIFIC, INC.
838 WALKER ROAD, SUITE 21-2105

(Street)
DOVER DE 19904

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Core Scientific, Inc./tx [ CORZ ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/04/2026 A 18,575(1) A $0 454,162 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents a restricted stock unit ("RSU") grant. The RSUs will vest in full on February 3, 2027, provided that the Reporting Person continues to provide service to the Issuer as a non-employee director on such date.
/s/ Todd DuChene, as Attorney-in-Fact 02/06/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Rozov Yadin report at Core Scientific (CORZ)?

Rozov Yadin reported receiving 18,575 Core Scientific common shares. The February 4, 2026 transaction is coded as an acquisition at $0 per share, reflecting an equity award rather than a market trade, and increased his directly held beneficial ownership to 454,162 shares.

What type of equity award did Core Scientific (CORZ) grant to director Rozov Yadin?

Core Scientific granted Rozov Yadin a restricted stock unit (RSU) award. The grant covers 18,575 RSUs that convert into common stock. These RSUs are part of his compensation as a non-employee director and are subject to a time-based vesting condition.

When do Rozov Yadin’s Core Scientific (CORZ) RSUs vest?

Rozov Yadin’s RSUs vest in full on February 3, 2027. Vesting is contingent on his continued service as a non-employee director through that date, meaning he must remain on the board until then to receive all underlying shares.

How many Core Scientific (CORZ) shares does Rozov Yadin own after this Form 4 transaction?

After the reported transaction, Rozov Yadin beneficially owns 454,162 shares. This figure reflects his direct ownership of Core Scientific common stock following the 18,575-share restricted stock unit grant reported on February 4, 2026.

Was cash paid for the Core Scientific (CORZ) shares granted to Rozov Yadin?

No cash was paid for the 18,575-share grant to Rozov Yadin. The Form 4 lists a transaction price of $0 per share, indicating the common stock was awarded as compensation rather than purchased in the open market.

What is Rozov Yadin’s role at Core Scientific (CORZ) in this Form 4 filing?

In this filing, Rozov Yadin is identified as a director of Core Scientific. He is marked as a non-employee director receiving a restricted stock unit grant, and the Form 4 is filed by one reporting person in that capacity.